DGIdb - CANERTINIB Drug Record

CANERTINIB chembl:CHEMBL31965 Antineoplastic

Alternate Names:

CI-1033
CANERTINIB
PD 183805
CI 1033
chembl:CHEMBL31965
chemidplus:267243-28-7
drugbank:05424
pubchem.compound:156414

Drug Info:

Drug Class	Kinase Inhibitors

(3 More Sources)

Publications:

Wang et al., 2006, HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors., Cancer Cell
Christensen et al., 2005, Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor., Mol. Cancer Ther.
Ward RA et al., 2013, Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)., J Med Chem
Li et al., 2008, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models., Oncogene
Hur W et al., 2008, Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase., Bioorg Med Chem Lett

CANERTINIB BMX

Interaction Score: 5.89

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18667312

Sources:
DTC
CANERTINIB EGFR

Interaction Score: 0.32

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
23930994 18408761

Sources:
DTC MyCancerGenome CIViC TTD
CANERTINIB CXCL8

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15956251

Sources:
NCI
CANERTINIB ERBB2

Interaction Score: 0.24

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical

PMIDs:
16843263

Sources:
MyCancerGenome JAX-CKB TTD
CANERTINIB AKT1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
CANERTINIB MTOR

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CANERTINIB YES1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

MyCancerGenome: CANERTINIB
- Version: 20-Jun-2017
Alternate Names:

CANERTINIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:

NCI: CI-1033

Version: 14-September-2017

Alternate Names:

C1880 NCI drug code

Drug Info:

Publications:

Christensen et al., 2005, Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor., Mol. Cancer Ther.

DTC: CANERTINIB

Version: 02-September-2020

Alternate Names:

CHEMBL31965 ChEMBL Drug ID

Drug Info:

Publications:

Hur W et al., 2008, Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase., Bioorg Med Chem Lett

Ward RA et al., 2013, Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)., J Med Chem

JAX-CKB: Canertinib
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Wang et al., 2006, HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors., Cancer Cell
CIViC: CANERTINIB
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Li et al., 2008, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models., Oncogene
TTD: CI-1033
- Version: 2020.06.01
Alternate Names:

D0YB3W TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL31965
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	Advanced Solid Tumor
Response Type	sensitive
Approval Status	Preclinical

CANERTINIB Drug Record

CANERTINIB chembl:CHEMBL31965 Antineoplastic

Alternate Names:

Drug Info:

Publications:

CANERTINIB BMX

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18667312

Sources: DTC

CANERTINIB EGFR

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 23930994 18408761

Sources: DTC MyCancerGenome CIViC TTD

CANERTINIB CXCL8

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15956251

Sources: NCI

CANERTINIB ERBB2

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type sensitive Approval Status Preclinical

PMIDs: 16843263

Sources: MyCancerGenome JAX-CKB TTD

CANERTINIB AKT1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

CANERTINIB MTOR

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

CANERTINIB YES1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

MyCancerGenome: CANERTINIB

Alternate Names: CANERTINIB Generic Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

NCI: CI-1033

Alternate Names: C1880 NCI drug code

Drug Info:

Publications: Christensen et al., 2005, Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor., Mol. Cancer Ther.

DTC: CANERTINIB

Alternate Names: CHEMBL31965 ChEMBL Drug ID

Drug Info:

JAX-CKB: Canertinib

Alternate Names:

Drug Info:

Publications: Wang et al., 2006, HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors., Cancer Cell

CIViC: CANERTINIB

Alternate Names:

Drug Info:

Publications: Li et al., 2008, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models., Oncogene

TTD: CI-1033

Alternate Names: D0YB3W TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL31965

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
18667312

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
23930994 18408761

Sources:
DTC MyCancerGenome CIViC TTD

Interaction Types & Directionality:

n/a

PMIDs:
15956251

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical

PMIDs:
16843263

Sources:
MyCancerGenome JAX-CKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

CANERTINIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Alternate Names:

C1880 NCI drug code

Publications:

Christensen et al., 2005, Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor., Mol. Cancer Ther.

Alternate Names:

CHEMBL31965 ChEMBL Drug ID

Publications:

Wang et al., 2006, HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors., Cancer Cell

Publications:

Li et al., 2008, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models., Oncogene

Alternate Names:

D0YB3W TTD Drug ID